<DOC>
	<DOCNO>NCT01516918</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy quadruple regimen ( VX-222 , telaprevir , pegylated interferon , ribavirin ) subject hepatitis C cirrhosis .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety Quadruple Therapy ( VX-222 , Telaprevir , Peginterferon-Alfa-2a , Ribavirin ) Subjects With Chronic Hepatitis C With Compensated Cirrhosis</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Subjects must genotype 1 Chronic Hepatitis C Subjects must compensate cirrhosis Subjects may either treatment na√Øve , may receive course Peg IFN/RBV without evidence response . Subjects consider relapsers Peg IFN/RBV , partial null responder consider Subjects hemophilia may permit enroll permission medical monitor Any previous treatment investigational drug drug regimen treatment hepatitis C , previous treatment approve protease inhibitor Any contraindication PegIFN RBV therapy Evidence hepatic decompensation : history ascites , hepatic encephalopathy , bleed esophageal varix A history acquire immunodeficiency infection , organ transplantation ongoing requirement immunosuppressive medicine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>